When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Talassemia alfa

Evidence last reviewed: 30 Apr 2026
Topic last updated: 19 Aug 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • sintomas de anemia
  • esplenomegalia
Full details

Other diagnostic factors

  • infância ou início da vida adulta
  • história familiar de talassemia alfa
  • sintomas de cálculos biliares
  • retardo de crescimento
  • história prévia de suplementação de ferro
  • icterícia
  • aspectos faciais dismórficos leves
  • hematopoese extramedular
Full details

Risk factors

  • etnia de uma região geográfica com incidência de malária
  • história familiar positiva
Full details

Diagnostic tests

1st tests to order

  • hemoglobina (Hb)
  • volume corpuscular médio (VCM)
  • hemoglobina corpuscular média (HCM)
  • contagem de eritrócitos
  • esfregaço de sangue periférico
  • percentual de reticulócitos
  • ferro sérico
  • ferritina sérica
Full details

Tests to consider

  • coloração de azul de cresil brilhante dos eritrócitos
  • eletroforese de Hb
  • fracionamento da Hb por cromatografia líquida de alta eficiência (HPLC)
  • reação em cadeia da polimerase (gap-PCR)
  • amplificação de múltiplas sondas dependentes de ligação
  • sequenciamento direto/dot-blot reverso
  • ressonância nuclear magnética (RNM) (hepática ou cardíaca)
  • dispositivos supercondutores de interferência quântica (SQUID)
  • biópsia hepática
Full details

Treatment algorithm

ACUTE

episódios hemolíticos agudos: gestante ou não gestante

crise aplástica transitória: gestante ou não gestante

ONGOING

não gestante

gestante

Contributors

Authors

Janet L. Kwiatkowski, MD, MSCE

Director

Thalassemia Program

Children’s Hospital of Philadelphia

Professor of Pediatrics

Perelman School of Medicine

University of Pennsylvania

Philadelphia

PA

Disclosures

JLK has participated in research trials of gene therapy sponsored by bluebird bio, Sangamo, Vertex, and Editas, and has participated in studies of pyruvate kinase activators sponsored by Agios and Forma Therapeutics. She has consulted for Agios, Forma, NovoNordisk, Chiesi, Biomarin, Regeneron, Vertex, and Bristol Myers Squibb (Celgene).

Acknowledgements

Dr Janet L. Kwiatkowski would like to gratefully acknowledge Dr Elizabeth A. Price and Dr Stanley L. Schrier, the previous contributors to this topic.

Disclosures

EAP declares that she has no competing interests. SLS has received US National Institutes of Health (NIH) research funds, has received funds for organising an educational symposium, and is an author of a number of references cited in this topic.

Peer reviewers

David H. K. Chui, MD, FRCPC

Professor of Medicine

Boston University School of Medicine

Boston

MA

Disclosures

DHKC is an author of a number of references cited in this topic. He has received research grants or salary from the US National Institutes of Health greater than 6 figures USD.

Piero Giordano, PhD

Professor of Clinical Biochemical Molecular Genetics

Human and Clinical Genetics Department

Leiden University Medical Center

Leiden

The Netherlands

Divulgaciones

PG declares that he has no competing interests.

Cornelis Harteveld, PhD

Clinical Molecular and Biochemical Geneticist

Department of Clinical Genetics

Leiden University Medical Center

Leiden

The Netherlands

Divulgaciones

CH declares that he has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Thalassaemia International Federation. Guidelines for the management of alpha-thalassaemia (2023). 2023 [internet publication].Texto completo

Northern California Comprehensive Thalassemia Center. Standards of care guidelines for thalassemia. 2012 [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Talassemia alfa images
  • Diferenciales

    • Anemia ferropriva
    • Talassemia beta
    • Hemoglobinas variantes (Hb E, Hb Lepore)
    Más Diferenciales
  • Guías de práctica clínica

    • Guideline for the management of conception and pregnancy in thalassaemia syndromes
    • Guidelines for the management of alpha-thalassaemia (2023)
    Más Guías de práctica clínica
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad